GlassScriptPhysician profile
William A Graber
NPI 1861486912
$49,460.81
in general payments reported to CMS, 2019-2025
15 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $98.52 · 2021: $23K · 2022: $201 · 2023: $13K · 2024: $552 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $24K · Food and Beverage: $1,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $24,093.35 |
| Food and Beverage | $1,876.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $48,342.82 | 2020-2025 | Da Vinci Surgical System |
| Novo Nordisk INC | $384.91 | 2019-2025 | Wegovy |
| Baxter Healthcare | $252.28 | 2025 | Floseal, Perclot |
| Medtronic, INC. | $119.17 | 2023 | Endoflip |
| Musculoskeletal Transplant Foundation INC. | $115.28 | 2024 | |
| Ethicon US, LLC | $41.03 | 2022-2025 | Echelon Flex |
| Stryker Corporation | $40.20 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2024-2025 | Gattex |
| Lemaitre Vascular, INC. | $33.53 | 2024 | Artegraft Vascular Graft |
| Lilly USA, LLC | $23.81 | 2025 | Zepbound |
| Abiomed | $19.61 | 2024 | Impella |
| Smith+Nephew, INC. | $13.59 | 2024 | Collagenase Santyl |
| Ambu INC. | $13.57 | 2024 | |
| Merck Sharp & Dohme LLC | $12.99 | 2020 | |
| Acell, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Graber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.